Is Mounjaro a Semaglutide? Understanding the Differences and Similarities

Last reviewed: June 10, 2026

Last updated: June 10, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Many people ask whether Mounjaro is a form of semaglutide, but the answer is no—they are two separate medications that work through different mechanisms in your body. Both belong to the GLP-1 receptor agonist class, but Mounjaro (tirzepatide) activates an additional pathway that semaglutide does not, making them uniquely suited for different individuals based on their genetic and metabolic profiles.

Semaglutide and Tirzepatide Are Different Medications

Semaglutide and tirzepatide (Mounjaro) are not interchangeable drugs, even though both were designed to help with weight loss and metabolic health. Semaglutide activates only the GLP-1 receptor, a single hormone pathway in your brain and gut that signals fullness and reduces appetite. Tirzepatide, by contrast, activates both GLP-1 and GIP receptors simultaneously, creating a dual-pathway effect that some patients find more effective.

The structural differences between these compounds mean they have different pharmacokinetics—how your body absorbs, distributes, and eliminates them. Semaglutide reaches peak blood levels within 1–3 days of injection, while tirzepatide works through a longer-acting mechanism that maintains steadier levels throughout the week. These timing differences can influence how quickly you feel results and how your body adapts to the medication over time.

How GLP-1 and GIP Pathways Affect Weight Loss Results

GLP-1 receptors are found throughout your brain's appetite centers, your pancreas, and your gastrointestinal tract, making semaglutide effective at reducing hunger and slowing stomach emptying. This single-pathway approach has strong clinical evidence: semaglutide achieved average weight loss of 15% in the STEP trials over 68 weeks. However, not every person responds equally to GLP-1 alone, which is where genetic variation plays a role.

Tirzepatide's dual mechanism—activating both GLP-1 and GIP—taps into an additional weight regulation pathway that can produce stronger metabolic effects in some individuals. In clinical trials, tirzepatide users lost up to 22% of their body weight, suggesting the GIP component enhances results for certain patients. Your genetic makeup, specifically variants in the GIPR genes, influences how strongly each medication will work for you, which is why personalized testing matters.

Similarities Between Semaglutide and Tirzepatide

Both medications reduce appetite by mimicking glucagon-like peptide-1, a natural hormone your body produces after eating. They slow gastric emptying (how fast food moves through your stomach), increase feelings of fullness, and help regulate blood sugar levels. Both are administered as once-weekly injections or daily oral formulations, offering flexibility based on your preference and lifestyle.

Common side effects are similar between the two: nausea, vomiting, constipation, and diarrhea occur more frequently during the first few weeks as your body adjusts. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. And both require dose escalation over several weeks to reach maintenance levels, though your total monthly cost remains flat regardless of your dose progression.

Why Genetic Testing Helps You Choose the Right Medication

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

The Precision Peptide Genetic Test provides 150+ genetic insights that map to your specific peptide metabolism, helping PlexusDx clinicians personalize your treatment plan from the start. Rather than guessing which medication suits you best, you get data-driven guidance based on your unique biology. This test is available for $298, allowing you to optimize your protocol based on genetic predisposition rather than trial and error.

Access Semaglutide and Tirzepatide Through PlexusDx

PlexusDx compounds both semaglutide and tirzepatide through licensed 503A compounding pharmacies, making them accessible in all 50 states without insurance requirements or membership fees. Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan), while Compounded Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan—and your dose may increase, but your price will not. Both medications are HSA/FSA eligible, helping reduce out-of-pocket costs for eligible patients.

If you prefer oral formulations, PlexusDx offers Oral Semaglutide at $289/mo (or $249/mo on the 6-month plan) and Oral Tirzepatide at $349/mo (or $279/mo on the 6-month plan), each with the same flat-pricing guarantee. For patients interested in exploring both pathways simultaneously, the GLP-Squared Injection (combining semaglutide and tirzepatide in one compound) is $289 per month month-to-month. Your PlexusDx clinician will recommend the best starting point based on your medical history, goals, and genetic profile once you add the Precision Peptide Genetic Test.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection is $289/mo month-to-month, or from $249/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test ($298) to personalize your protocol from day one.

Frequently Asked Questions

Is Mounjaro the same as semaglutide?

No. Mounjaro is the brand name for tirzepatide, which activates GLP-1 and GIP receptors. Semaglutide activates only GLP-1 receptors. They are distinct medications with different mechanisms, though both help reduce appetite and support weight loss through different biological pathways.

Which medication produces better weight loss results?

Clinical trials show tirzepatide achieved up to 22% weight loss, while semaglutide achieved approximately 15% in comparable studies. However, individual results vary based on genetics, metabolism, and adherence. Your genetic profile (including GIPR variants) influences which medication will work most effectively for your body.

Can I switch from semaglutide to tirzepatide or vice versa?

Yes, many patients switch between medications under clinical guidance if one isn't producing desired results after adequate time and dose titration. PlexusDx clinicians can help you transition safely and monitor your response. Genetic testing through the Precision Peptide Genetic Test can inform whether a switch is likely to improve your outcomes.

What does PlexusDx charge for semaglutide and tirzepatide?

Compounded Semaglutide Injection is $189/mo month-to-month (or $149/mo on the 6-month plan), and Compounded Tirzepatide Injection is $289/mo month-to-month (or $249/mo on the 6-month plan). Your dose may increase over time, but your monthly price remains flat. Both are available through licensed 503A compounding pharmacies nationwide and are HSA/FSA eligible.

How does the Precision Peptide Genetic Test help me choose between these medications?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Medvi Semaglutide
• Bioverse Semaglutide
• Ro Semaglutide
• Mochi Semaglutide

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.